Holen Sie sich die Stockscreener-App
37.53
1.45%
-0.5652
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Protagonist Therapeutics chief medical officer sells shares for tax obligations - Investing.com India
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $53.78 - Defense World
Protagonist Therapeutics CFO Ali Asif reports stock sale By Investing.com - Investing.com South Africa
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 6.2%Time to Sell? - MarketBeat
Long Term Trading Analysis for (PTGX) - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% HigherStill a Buy? - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $53.78 Consensus PT from Brokerages - MarketBeat
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics announces executive role change By Investing.com - Investing.com Australia
Protagonist Therapeutics announces executive role change - Investing.com
Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Officer, Grants Equity Awards - StockTitan
Protagonist Therapeutics Reports Granting of Inducement Awards - AccessWire
Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4%What's Next? - MarketBeat
Principal Financial Group Inc. Acquires 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Principal Financial Group Inc. Purchases 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Decreases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Where are the Opportunities in (PTGX) - Stock Traders Daily
Franklin Resources Inc. Acquires 45,674 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 2.3%Here's Why - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Barclays PLC Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HighTower Advisors LLC Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wellington Management Group LLP Makes New $1.35 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Batesville Daily Guard
Protagonist Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Y Intercept Hong Kong Ltd Trims Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical trials - Investing.com
State Street Corp Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics’ (PTGX) Buy Rating Reiterated at HC Wainwright - Defense World
Clear Street sets $63 target on Protagonist Therapeutics By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
BTIG maintains shares target on Protagonist Therapeutics, cites trial By Investing.com - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Fmr LLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist's Rusfertide Shows Breakthrough Results in Phase 2 PV Study: 54% Hit Key Treatment Goals - StockTitan
The Goldman Sachs Group Begins Coverage on Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Weiss Asset Management LP Makes New $2.81 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Point72 Asset Management L.P. Sells 694,862 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at The Goldman Sachs Group - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by BMO Capital Markets - MarketBeat
BMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Technical Data - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by RTW Investments LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by HighVista Strategies LLC - MarketBeat
Walleye Capital LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
0.75%
8.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):